Business Wire

Acelity Enters Agreement to Transition Systagenix Manufacturing Facility to Scapa Healthcare

Jaa

Today, Acelity announced an agreement to sell its advanced wound dressings manufacturing facility located in Gargrave, England, to Scapa Healthcare. In conjunction with the transfer of the facility upon close of the transaction, more than 350 employees will transition to Scapa in support of a manufacturing agreement with KCI, an Acelity Company. The manufacturing agreement will assure continued supply of key products and components which advance KCI’s global growth strategy in advanced wound dressings (AWD).

Upon completion of the transaction, the manufacturing operations, sterilization services, warehouse facilities, R&D and regulatory support functions in Gargrave, England, will be transferred to Scapa Healthcare.

Building upon the momentum of the Company’s recent acquisition of Crawford Healthcare, this strategic transaction allows KCI to further enhance its position as a global leader in advanced wound care. The transfer of the Gargrave facility enables KCI to rely upon Scapa’s manufacturing expertise on key product lines, while enhancing KCI’s focus on marketing and commercializing the growing AWD business.

“The global advanced wound care market is large and growing rapidly. Expanding the KCI AWD dressing portfolio, including the market-leading collagen dressing PROMOGRAN PRISMA™ Matrix and super-absorbent KerraMax Care® range, to further complement our negative pressure wound therapy products is imperative to our growth objectives,” said R. Andrew Eckert, President and CEO of Acelity. “This transaction will allow us to maintain and increase our innovation and product development efforts, as well as focus on the commercial execution of our AWD business, while we strategically invest to expand in other areas, such as our leading digital wound care and surgical solutions.”

Until the transaction is finalized, Acelity will continue to manage the Gargrave facility. Acelity anticipates closing the transaction early October 2018.

About Acelity

Acelity L.P. Inc. is a global advanced wound care company committed to developing innovative healing solutions for customers and patients across the care continuum. Its subsidiary, KCI, is the most trusted brand in advanced wound care. The unsurpassed KCI product portfolio is available in more than 90 countries and delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Committed to advancing the science of healing, KCI sets the standard for leading advanced wound therapy innovation.

Contact information

Acelity
Kathryn Skeen, +1-210-882-2067
Corporate Communications
kathryn.skeen@acelity.com
or
Jathan Tucker, +1-210-255-6816
Investor Relations
jathan.tucker@acelity.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

PTC Adds Artificial Intelligence and Generative Design Capabilities to Enhance and Expand its CAD Portfolio with Acquisition of Frustum20.11.2018 15:12Tiedote

PTC (NASDAQ: PTC) today announced that it has acquired Frustum Inc., an advanced generative design software company, for approximately $70 million. Frustum’s technology for generative design—an approach that leverages artificial intelligence (AI) to generate design options—is a transformative addition to the PTC Creo portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005326/en/ PTC Adds Artificial Intelligence and Generative Design Capabilities to Enhance and Expand its CAD Portfolio with Acquisition of Frustum (Graphic: Business Wire) Based in Boulder, Colorado, Frustum offers patented desktop and cloud-based engineering software that enables designers and engineers to go beyond the limits of their personal experience by leveraging powerful AI capabilities that guide the discovery of high-performance, next-generation product designs. “PTC is pushing the boundaries of innovation with this acquisition,” said Jim

United First Partners Launches UFP Fintech20.11.2018 15:00Tiedote

United First Partners (“UFP”), a leading independent Research, Brokerage, Advisory & Investment group is pleased to announce the launch of its latest venture: UFP Fintech. UFP Fintech invests in early stage Fintech, Proptech and Legaltech startups. Under the leadership of the entity’s CIO Christophe Petetin, a veteran investor in the Fintech space with an unparalleled investment track record in Fintech start-ups, UFP Fintech aims to become a global leader in Early Stage Fintech Investments. In recent years, Christophe and the UFP Fintech team have seeded a major unicorn and several other market leading entities. Christophe is a premier Fintech thought leader, who also acts in an advisory capacity to governmental and regulatory bodies, such as the FCA and ISO 20022 to create the next generation of standards for Fintech, payments, data, securities & digital currencies. Christophe commented “The financial industry is getting rebuilt from the ground up creating unprecedented opportunities.

LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases20.11.2018 14:00Tiedote

Danish dermatology specialists LEO Pharma and California rare disease pioneers PellePharm today announced a strategic development and commercialization collaboration to address unmet medical needs across various skin diseases with no approved treatments, advancing innovation and access to potential therapies for patients with life-altering conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC), two distinct and rare forms of skin cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005227/en/ “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin diseases. Supporting our ambitious 2025 strategy, it marks LEO Pharma’s entrance in rare skin diseases and it offers a unique opportunity to bring the first treatment forward to people suffering from a very severe skin disease for which there currently are no approved therapies,” sai

IDEMIA Provides SK Telecom in South Korea with GMSA Compliant Smart Connect Solution to Activate and Manage eSIM Device Lifecycles20.11.2018 12:00Tiedote

IDEMIA, the global leader in Augmented Identity, is proud to have been selected by SK Telecom, the number one telecommunication operator in South Korea, to launch the first eSIM Connected watch based on GSMA Consumer standards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005231/en/ Crédits : IDEMIA As a leading actor in the telecom field, IDEMIA is at the forefront of the digital revolution and is committed to bringing protected and convenient experiences to mobile operator customers. Leveraging its industrial leadership and appetite for innovation, IDEMIA will be providing SK Telecom its GSMA compliant solution. Based on IDEMIA’s Smart Connect Subscription management solution also known as remote SIM provisioning, the technology remotely connects the eSIM of the smart watch to the SK Telecom’s network without inserting a physical SIM card. This technology is also compliant with the latest GSMA standards ensuring in

AURAK Hosts ICEWES 201820.11.2018 10:51Tiedote

The American University of Ras Al Khaimah (AURAK) hosted their annual three-day conference, The International Conference on Energy, Water, and Environmental Sciences (ICEWES), in cooperation with the Arab German Young Academy of Sciences and Humanities (AGYA) and the International Canadian Association for Sharing Knowledge and Sustainability (IASKS) to bring together researchers and scientists with interests in solving energy, water, and environmental related issues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005997/en/ ICEWES 2018 opening ceremony audience at the American University of Ras Al Khaimah (Photo: AETOSWire) The first day of ICEWES commenced with a morning session including the UAE National Anthem, a recitation from the Holy Quran, a welcoming speech from the Vice President of Academic Affairs and Student Success of AURAK, Professor Stephen Wilhite, an AGYA overview from Managing Director, Dr. Sabine Do

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)20.11.2018 09:30Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227). IPN01087 is a compound that targets cancer cells in patients with advanced solid tumors which express the Neurotensin Receptor Subtype 1 (NTSR1). The key objective of the Phase I dose-escalation trial (EUDRACT Number 2017-001263-20) is to evaluate the safety and activity, as well as to identify the optimum systemically-administered dose of radiation to treat patients with any of the following solid tumors expressing NTSR1: pancreatic ductal adenocarcinoma, colorectal cancer, gastric cancer, gastrointestinal stromal tumors, Ewing sarcoma and squamous cell carcinoma of the head and neck. Alexandre Lebeaut, Executive Vice President, R&D and Chief Scientific Officer, Ipsen, said: “Ipsen is committed to bringing to cancer patients innovative systemic radiation therapy with targeted ra

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme